The latest headlines across every section, pulled from official and open-access sources.
The TUXEDO-2 (Ultrathin Strut vs. Xience in a Diabetic Population With Multivessel Disease 2—India Study) trial demonstrated that among patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)...
The new 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome is the first ever to address the "interrelated condition characterized by the interconnections among metabolic risk factors (including obesity and type 2 diabetes)...
Sanofi has stopped a phase 3 autoimmune clinical trial early after an interim analysis found the therapy was “unlikely to provide sufficient efficacy.” The setback eliminates one opportunity for a key late-phase program and continues the “bumpy ride” for Sanofi’s pipeline.
Parabilis Medicines’ IPO has lived up to the hype—securing $670 million for the largest listing in the biotech sector’s history.
Novartis has stuck on a second deal with Orionis Biosciences, this time handing $40 million upfront to the molecular glue biotech to work on “challenging therapeutic targets across multiple disease areas.”
Ethyreal Bio has exited stealth with $101 million, joining the queue of companies preparing to challenge Amgen’s Tepezza.
Bay Area biotech SonoThera is bubbling to a clinical boil after raising a $125 million series B with the backing of some of the biggest names in pharma.
Since GLP-1 drugs like Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide took the world by storm for their potent treatment of diabetes and obesity, they have also been plagued by a clinical conundrum. In some studies, the peptides seem to possess antidepressant effects, while in others they’ve been linked to worse mental health and even increased suicidality.
In this week’s View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care.
Even as industry watchers pit the two assets against one another, it’s too early to say whose next-generation incretin stands supreme between Novo Nordisk’s CagriSema and Eli Lilly’s retatrutide, Novo’s chief scientific officer suggested to Fierce at the ADA 2026 Scientific Sessions in New Orleans this past Sunday.
When Charles River Laboratories CEO Birgit Girshick started her career as an executive assistant with the company in Germany in 1989, she didn’t know what was possible for her career in the world of biotech. She did know she wanted to make a difference.
Patients with low plasma renin levels had a more pronounced blood pressure (BP) reduction with spironolactone/dapagliflozin vs. dapagliflozin alone, in addition to seeing a more favorable impact on cardiovascular structure and function, while aldosterone levels exhibited no predictive value in treatment response...
Novo Nordisk CEO Mike Doustdar told Fierce in an interview that he always believed the Big Pharma “did actually need to become more competitive.”
Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb’s Sotyktu to strengthen its hand ahead of an anticipated plaque psoriasis launch next year.
Caribou Biosciences has linked its CAR-T cell therapy candidate to 17.1-month median progression-free survival, adding to evidence that the off-the-shelf treatment can match the efficacy of autologous products in lymphoma patients.
Kardigan has sewn up its IPO plans, with the cardiovascular biotech expecting to bring in a cozy $320 million from its planned Nasdaq listing.
Fierce Biotech is returning to the U.K. in November for a day of curated discussions and networking at The Savoy, London’s iconic hotel.
First large-scale atlas of senescent cells could help inform future therapies for age-related diseases.
Rigid adenoviral platforms can derail GMP progress. Learn how adaptive, adenovirus-specific strategies reduce risk from development to scale.
When compared with angiography guidance, quantitative flow ratio (QFR)-guided PCI improved five-year clinical outcomes with benefits primarily achieved in the first two years, according to a follow-up study of the multicenter, sham-controlled FAVOR III trial published June 10 in JACC.
A long-term follow-up of the CENTRAL and DIRECT-PLUS trials published in Circulation suggests that despite long-term weight regain, visceral fat reduction during lifestyle intervention is associated with sustained improvements in metabolic health.
Predicta Biosciences, a precision oncology specialist, is teaming with the Clínica Universidad de Navarra’s CIMA Lab Diagnostics clinic to offer an assay focused on blood cancers.
As cybersecurity threats have proliferated across industries in recent years, biopharma companies have emerged as prominent targets, with intellectual property, patient data and other sensitive information at stake. Now, Novo Nordisk is the latest drug giant to report a data breach.
Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are among the casualties in another round of layoffs from the South San Francisco subsidiary of Roche. The departures are part of a restructuring of the Genentech Research and Early Development (gRED) group. The company did not reveal how many positions are being affected.